TradingMenu expanded
Forge Markets Browse Companies
DataMenu expanded
Forge Data Private Market Index IPO Stock Tracker
SolutionsMenu expanded
For Institutions For Shareholders For Investors For Companies In Europe
InsightsMenu expanded
All Insights Blog Reports Videos Webinars
Popular Topics
Buying Pre-IPO Shares Selling Pre-IPO Shares Private Market Reports Private Market Data & Analytics Startup News
AboutMenu expanded
About Us Team Investor Relations People & Culture Careers FAQs
Log In Sign Up
Trading Menu expandedTrading
Forge Markets
Browse Companies
Data Menu expandedData
Forge Data
Private Market Index
IPO Stock Tracker
Solutions Menu expandedSolutions
For Institutions
For Shareholders
For Investors
For Companies
In Europe
Insights Menu expandedInsights
All Insights
Blog
Reports
Videos
Webinars
Popular Topics
Buying Pre-IPO Shares
Selling Pre-IPO Shares
Private Market Reports
Private Market Data & Analytics
Startup News
About Menu expandedAbout
About Us
Team
Investor Relations
People & Culture
Careers
FAQs
Trading / Browse Companies / Impel NeuroPharma Stock

Impel NeuroPharma Stock

impelnp.comHealthcareFounded: 2008Funding to Date: $122.85MM

Impel NeuroPharma is a biotechnology company devoted to creating life-changing, innovative therapies for central nervous system (CNS) diseases.

Learn more about Impel NeuroPharma IPO
Register for Details

For more details on financing and valuation for Impel NeuroPharma, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

OverviewFinancingsValuation

Enterprise Value (based on primary financings)

Powered by Forge Data
Enterprise Value

View Enterprise Value for Impel NeuroPharma.

Register Today

Team

Management Team

Jon Congleton
Chief Executive Officer, President & Board Member
Meghan Swardstrom
Vice President, Clinical Operations
Ellen Lubman
Chief Business Officer
Scott Youmans
Senior Vice President, Engineering
Mike Malafronte
Vice President of Quality Assurance
John Hoekman Ph.D
Co-Founder, Chief Scientific Officer & Board Member
Lynn Gold Ph.D
Senior Vice President, Regulatory
Stephen Shrewsbury
Chief Medical Officer

Board Members

Ali Satvat
Kohlberg Kravis Roberts
H. Stewart Parker
Mahendra Shah Ph.D
Vivo Capital
David Allison Ph.D
5AM Ventures
Diane Wilfong
John Hoekman Ph.D
Robert Mittendorff MD
Norwest Venture Partners
Aaron Royston MD
venBio
James Young Ph.D
5AM Ventures
Jon Congleton
Timothy Nelson

Other companies like Impel NeuroPharma in the Healthcare sector

Altos Labs
Sector
Healthcare
Last Round Est. Valuation
$3.67B
Acelyrin
Sector
Healthcare
Last Round Est. Valuation
$809.52MM
Colossal Biosciences
Sector
Healthcare
Last Round Est. Valuation
$1.01B
Paradromics
Sector
Healthcare
 
 
Grail
Sector
Healthcare
Last Round Est. Valuation
$4.26B
OURA
Sector
Healthcare
 
 
Artera
Sector
Healthcare
Last Round Est. Valuation
$396.01MM
Synchron
Sector
Healthcare
Last Round Est. Valuation
$400.53MM
Alzheon
Sector
Healthcare
Last Round Est. Valuation
$1.53B

News

Market Screener 10/17/2019
Impel NeuroPharma : Announces Appointment Of Diane Wilfong To Board Of Directors
FinSMEs 12/07/2018
Impel NeuroPharma Closes $67.5M in Series D Financing | FinSMEs
Impel NeuroPharma, a biotech company focused on developing therapies for the treatment of CNS disorders, completed a $67.5m Series D financing

Trending Companies

Frequently Asked Questions

Updated on: Jun 3, 2023